##1. The Myth of AAV Vector Non‑integration and the Reality of Potential Risks Historically, adeno‑associated virus (AAV) has been described as remaining in the cytoplasm as an episome without integrating into the host genome. Because of this property, AAV has been regarded as a safe delivery vehicle with virtually no risk of insertional mutagenesis‑driven oncogenesis, unlike lentivirus or retrovirus, and has served as the core platform for numerous rare‑disease gene therapies (e.g., Zolgensma, Luxturna). However, a recent case of a brain tumor in a 9‑year‑old boy demonstrated for the first time in humanity that AAV can, albeit at a very low frequency, integrate into the genome and that such integration can be the direct cause of malignancy.

##2. Causal Relationship Revealed by Precision Sequencing: Integrated AAV and Activation of Oncogenes Whole‑genome sequencing (WGS) of the patient’s tumor tissue revealed that AAV vector DNA sequences were precisely inserted either disrupting tumor‑suppressor genes or landing near specific oncogenes. Notably, the strong promoter sequence carried by the inserted viral vector drove abnormal over‑expression of neighboring genes, inducing uncontrolled cellular proliferation. This provides molecular‑level evidence that the “integration site” and “transcriptional activation” of the vector are direct drivers of tumorigenesis, not a random coincidence.

##3. Tragedy of Low Probability: Overall Risk and Significance of an Isolated Case The investigators emphasized that this event is exceedingly rare and that the overall risk of gene therapy remains low. Nevertheless, the confirmation that a previously assumed “zero” risk actually exists mandates a comprehensive reassessment of safety evaluation methods. The fact that insertional events can occur even in largely post‑mitotic tissues such as the brain and lead to malignant tumors underscores the need for stricter safety factors in dose selection and vector design.

##4. Paradigm Shift in Gene‑Therapy Monitoring and Vector Design This report is important because it will fundamentally alter the regulatory landscape for the AAV platform, which underpins the global gene‑therapy market. Future product approvals will require high‑resolution mapping data on insertional mutagenesis potential, and long‑term cancer surveillance will become a standard of care rather than an optional follow‑up. Moreover, next‑generation safety‑by‑design strategies—such as incorporating insulator sequences that block genomic influence or engineering vectors that completely prevent genomic integration—are expected to become core competitive advantages for the industry.